As IDO and PDL1 are often co-expressed along with frequent immune infiltration in recurrent tumor samples, a possible treatment strategy could be co-inhibition with anti-IDO and anti-PD-1/PDL1 antibodies or boosting the already present IDO- and/or PDL1-specific T cells with a vaccine [42]. The gene discussed is CD274; the disease is neoplasm.